Abstract | The division of medulloblastoma into different subgroups by microarray expression profiling has dramatically changed our perspective of this malignant childhood brain tumour. Now, the availability of next-generation sequencing and complementary high-density genomic technologies has unmasked novel driver mutations in each medulloblastoma subgroup. The implications of these findings for the management of patients are readily apparent, pinpointing previously unappreciated diagnostic and therapeutic targets. In this Review, we summarize the 'explosion' of data emerging from the application of modern genomics to medulloblastoma, and in particular the recurrent targets of mutation in medulloblastoma subgroups. These data are currently making their way into clinical trials as we seek to integrate conventional and molecularly targeted therapies.
Central nervous system (CNS) tumours are the second most prevalent cancers in children (after leukaemia) and remain the leading cause of cancer-related mortality in childhood 1, 2 . Medulloblastoma is the most common malignant childhood brain tumour. Overall survival rates for patients with medulloblastoma have reached 70-80% using treatment protocols that include a combination of surgery, cranio-spinal radiotherapy (in children ≥3 years of age) and chemotherapy [3] [4] [5] . Current risk stratification tools have been in place for decades and are solely based on clinical features, including age at diagnosis, extent of surgical resection, metastatic status and, in some cases, histological features. Infants (≤3 years of age), patients with residual tumour (≥1.5 cm 2 in size) following neurosurgery and those exhibiting leptomeningeal dissemination at the time of diagnosis are all considered to be high risk, and all other patients are deemed to be average risk 6 . Although conventional therapies can cure a large proportion of patients with medulloblastoma, the majority of survivors suffer from long-term side effects, including developmental, neurological, neuroendocrine and psychosocial deficits [7] [8] [9] . Molecular stratification of patients with medulloblastoma has not yet been routinely implemented in the clinic, and the use of rational, molecularly targeted therapy for this disease is still in its infancy 10, 11 . Through an improved understanding of the molecular and genetic basis of medulloblastoma, it is anticipated that in the future patients will be stratified and treated according to the biological makeup of their disease, which will hopefully lead to improved patient outcomes with reduced sequelae.
Studies of heritable forms of medulloblastoma have provided the first insights into the processes that underlie the disease 12 . In the 1990s, Gorlin syndrome was confirmed to be attributable to inherited mutations of the patched 1 (PTCH1) tumour suppressor gene (TSG) on chromosome 9q22.32 . This discovery paved the way for several follow-up studies, which revealed recurrent somatic mutations of PTCH1 in sporadic medulloblastomas [16] [17] [18] . The sonic hedgehog (SHH) pathway, a developmental signalling axis in which PTCH1 normally imposes an inhibitory effect, is aberrantly activated in about one-third of all medulloblastomas 19 . Activation of SHH signalling in these tumours results from recurrent mutations and/or copy number aberrations that target multiple specific levels of the pathway (discussed below). Individuals with Turcot syndrome are susceptible to the development of colorectal cancer and brain tumours, including medulloblastoma. Turcot syndrome consists of two subtypes: type II cases exhibit an increased risk of medulloblastoma owing to inactivating germline mutations in adenomatous polyposis coli (APC) -a TSG that negatively regulates β-catenin, which is the key effector of the WNT signalling pathway 20 . Deregulation of the WNT pathway secondary
Leptomeningeal dissemination
Metastasis to the leptomeninges (arachnoid mater and pia mater) that wrap the brain and spinal cord. Metastatic medulloblastoma cells typically disseminate to the leptomeninges via the cerebrospinal fluid.
Gorlin syndrome
Also known as nevoid basal cell carcinoma syndrome (NBCCS). An autosomal dominant condition in which affected individuals harbour germline mutations in patched 1 and the cells of which display aberrant activation of the sonic hedgehog signalling pathway. Individuals exhibit a variety of developmental defects including jaw cysts, palmar pits and skeletal abnormalities and they are predisposed to the development of extensive basal cell carcinomas and medulloblastoma, among other cancers.
Turcot syndrome
Typically an autosomal dominant condition characterized by multiple adenomatous colon polyps and predisposition to colorectal cancer and brain tumours. The genetic basis is linked to mutations in adenomatous polyposis coli, which predisposes to medulloblastoma, or to the mismatch repair genes MLH1 or PMS2, which predispose to glioblastoma.
to somatic mutations of the β-catenin gene, CTNNB1 (REFS 21, 22) , is now recognized to occur in ~10% of sporadic medulloblastomas 19 . Extrapolation of the insights gained from these medulloblastoma susceptibility syndromes to candidate gene approaches has revealed additional oncogenes and TSGs that are altered in familial and sporadic medulloblastoma, although mutations in most of these genes are exceedingly rare [23] [24] [25] [26] [27] [28] [29] . Recent technological advances in nucleic acid sequencing along with the availability of high-density microarrays of unprecedented resolution have opened new doors in the cancer genomics arena 30, 31 . Such next-generation technologies are now being applied to medulloblastoma, and results from the first wave of medulloblastoma genome-sequencing studies have now been published [32] [33] [34] [35] . In this Review, we highlight the recent breakthroughs that have been made in the field of medulloblastoma genomics and discuss how findings from large-scale copy number and next-generation sequencing studies will influence ongoing basic research and translate to improved treatment options for patients with medulloblastoma.
Molecular subgroups of medulloblastoma
During the past few years, array-based transcriptional profiling of moderate-to-large cohorts of primary medulloblastomas has uncovered the existence of distinct molecular subgroups [36] [37] [38] [39] [40] [41] . Despite the variable numbers of transcriptional clusters that have been identified in each of these genomic studies, the current consensus is that medulloblastoma consists of four core subgroups: WNT, SHH, Group 3 and Group 4 (REF. 42 ). Medulloblastoma subgroups have highly disparate cytogenetics, mutational spectra and gene expression signatures, in addition to divergent clinical phenotypes such as patient demographics, tumour cell histology and patient outcome 19, 43, 44 (TABLE 1) . The establishment of the current four-subgroup structure of medulloblastoma has, in a very short time, revamped how medulloblastoma is viewed and studied, both in the laboratory and in the design of future clinical trials 45, 46 . What for many years was considered, and treated, as a single tumour entity 47 , is now regarded as four very distinct diseases, each requiring different therapeutic approaches.
WNT medulloblastoma. WNT subgroup medulloblastomas currently have the best prognosis of any subgroup; >95% of these patients will survive their disease 3, 5 (TABLE 1) . WNT cases are equally distributed between males and females, despite a male to female preponderance of ~1.5/1 in medulloblastoma overall. Cases of WNT medulloblastoma are the least common of the four subgroups, accounting for only about one in every ten diagnoses. These tumours typically occur in children over the age of three, exhibit classic histology and are infrequently metastatic 19 . Medulloblastomas harbouring somatic mutations of CTNNB1 that promote stabilization and nuclear localization of β-catenin belong to the WNT subgroup 37, 48 . In addition to harbouring nearly ubiquitous CTNNB1 mutations, WNT subgroup medulloblastomas often carry heterozygous TP53 (which encodes p53)
At a glance
• Medulloblastoma is the most common malignant paediatric brain tumour and is a leading cause of cancer-related morbidity and mortality in children.
• Integrative genomic studies have recently identified at least four distinct molecular subgroups of medulloblastoma -WNT, sonic hedgehog (SHH), Group 3 and Group 4 -which exhibit highly discriminate transcriptional, cytogenetic and mutational spectra in addition to divergent patient demographics and clinical behaviour.
• Recent next-generation sequencing of medulloblastoma samples and their matched constitutional DNA has led to the identification of a multitude of previously unknown candidate genes that are somatically mutated in this cancer, including many that are mutated in a subgroup-specific manner.
• Different mechanisms of structural variation, including somatic copy number aberrations, chromothripsis and tetraploidy, contribute to a considerable proportion of medulloblastomas and may be more prevalent than recurrent somatic mutations in Group 3 and Group 4 tumours.
• Despite the extensive amount of copy number and sequence data that has become available for large cohorts of medulloblastoma, most Group 3 and Group 4 tumours cannot be attributed to a specific driver mutation or mutations, suggesting that additional mechanisms, such as epigenetic deregulation, may also have a prominent role.
• Research on medulloblastoma during the next few years will be focused on the functional validation of candidate genes and molecular processes that were reported to be deregulated in the recent human genomic studies. The generation of faithful models that recapitulate these mutational events will become a priority, and such reagents will be a valuable resource for the development of rational, molecularly targeted therapies.
Next-generation sequencing
Sequencing technologies emerging since 2005 that have substantially increased the output of the nucleic acid sequencing process. They produce millions to hundreds of millions of typically short sequence reads (50-400 bp) from amplified DNA clones.
Classic histology
The most common histological subtype of medulloblastoma, displaying prototypical sheets of repetitive small cells with a high nuclear/cytoplasmic ratio and round nuclei. Found in all medulloblastoma subgroups. mutations 49, 50 . WNT tumours are readily identifiable by a WNT gene expression signature 51 , and the nuclear accumulation of β-catenin is routinely used as a biomarker for WNT pathway activation in both research settings and clinical settings. Cytogenetically, WNT medulloblastomas exhibit mostly balanced genomes 19 , with the exception of monosomy 6, a hallmark chromosomal aberration that is found in almost all cases of WNT medulloblastoma and that is very rarely seen in the other subgroups.
Current evidence from mouse models of medulloblastoma, in combination with data on subgroup-specific somatic events from cohorts of human medullo blastoma, suggest that mutations are subgroup specific and, therefore, must be highly matched to their correct cell of origin (that is, external granule cell layer (EGL) for SHH medulloblastoma Mice expressing the activated Ctnnb1 transgene in the context of Trp53 deletion develop classic medulloblastomas (penetrance of ~15%) after a fairly long latency. Extensive transcriptional characterization of tumours derived from these mice has established their association with human WNT medullo blastoma counterparts. These tumours arise from the dorsal brainstem, in contrast to the EGL-derived medullo blastomas that arise in Ptch1 +/− mice that model the human SHH medullo blastoma subgroup (discussed below). In a recent medulloblastoma genomics study, Robinson et al. 32 (discussed below) supplemented the established WNT mouse model by adding a PI3K catalytic-α 
99
. ‡ Driver genes are determined by the relative frequency of mutations or SCNAs affecting the genes in each subgroup, as described in recent medulloblastoma sequencing and copy number studies [32] [33] [34] 99 . Nature Reviews | Cancer 
Dorsal brainstem
The hindmost parts of the structure of the brainstem. (TABLE 1) . These tumours exhibit a curious bimodal age distribution, accounting for the majority of both infant and adult medulloblastomas but for only a minority of childhood cases. Desmoplastic (or nodular) histology is almost exclusively restricted to SHH medulloblastomas 54 , whereas classic and large-cell or anaplastic (LCA) cases also occur, but they are not confined to this subgroup.
Germline mutations that affect either PTCH1 or suppressor of fused homologue (SUFU), which encode negative regulators of the SHH signalling pathway, result in the development of SHH medulloblastoma 13, 14, 24, [55] [56] [57] . Somatic mutations of PTCH1, and occasionally additional components of the SHH pathway, as well as somatic copy number aberrations (SCNAs) affecting the SHH target genes MYCN and GLI family zinc finger 2 (GLI2), are typical of this subgroup [37] [38] [39] [40] . The SHH medulloblastoma genome contains substantially more regions of chromosomal gain and loss than WNT medulloblastoma, including frequent deletions of chromosomes 9q and 10q, as well as other less common aberrations 19 (TABLE 1) .
Faithful mouse models recapitulating human SHH medulloblastoma have been available for more than a decade and have long been the 'workhorses' in medulloblastoma basic research 58, 59 .
Ptch1
+/− mice 60, 61 and transgenic mice that overexpress activated smoothened (SMO), neurogenic differentiation 2 (ND2; also known as Neurod2)-Smoa1 (REFS 62, 63) , are among a multitude of mouse models that mimic defects in the canonical SHH pathway that develop medulloblastomas with variable frequencies (TABLE 2) . Mouse SHH medulloblastomas can be initiated in cerebellar granule neuron precursors (CGNPs) of the EGL [64] [65] [66] and those from cochlear nuclei 67 , or from neural stem cell populations residing in the subventricular zone 65 .
Antagonists of SHH signalling, primarily those inhibiting the pathway at the level of SMO, are currently an area of active interest in the pharmaceutical industry and are in clinical trials for medulloblastoma 10, 11 . Despite showing a pronounced initial response to treatment with SMO inhibitors, both humans and mice acquire resistance to the treatment and relapse within a short period, suggesting that such inhibitors may be ineffective when administered as a monotherapy [68] [69] [70] [71] [72] . Furthermore, tumours with amplifications in key SHH pathway target genes (that is, GLI1, GLI2 or MYCN) 36, 39, 40, 73 might have an inherent primary resistance to these drugs. Nevertheless, young infants harbouring germline PTCH1 mutations, such as those observed in Gorlin syndrome medulloblastoma, may be ideally suited for targeted therapy with SMO inhibitors, although concerns of complications with normal development in this age group have been raised 74 . In the future, appropriate patient selection will be crucial in order to maximize the opportunity for effective treatment with SHH antagonists.
Group 3 medulloblastoma.
Patients with Group 3 medulloblastoma currently have the worst outcome of the four subgroups 19, 39, 40 (TABLE 1) . These tumours are more common in males, restricted to paediatric patients, frequently of the LCA subtype, and nearly 50% are metastatic at the time of diagnosis 19 
.
Focal, high-level amplification of the MYC protooncogene is highly enriched in Group 3 medulloblastoma, and almost all cases exhibit aberrant MYC expression 39, 40 . The Group 3 genome exhibits high levels of genomic instability and often harbours gains of
Box 1 | Cellular origins of medulloblastoma subgroups
The identification and characterization of the normal cells that undergo neoplastic transformation and that give rise to cancer is a topic of keen interest to the medical research community. In parallel to deciphering the range of somatic genomic alterations that are present in a given cancer, assigning an identity to the cell or cells of origin is an essential step for gaining a more comprehensive understanding of tumorigenesis 168 . By knowing which cells are susceptible to transformation, experimental approaches that are intended to functionally characterize candidate genes can be undertaken in the correct cellular context, and strategies for specifically targeting these cells of origin can be designed and tested.
Considerable insight into the cellular origins of medulloblastoma has been gained during the past few years, partially owing to the recent genomic characterization of medulloblastoma subgroups. The mapping of transcriptional profiles from human medulloblastoma subgroups to transcriptional data generated from normal cells of the developing mouse cerebellum or data from genetically engineered mouse medulloblastomas has implicated cellular origins for three of the four medulloblastoma subgroups. WNT medulloblastomas arise in lower rhombic lip progenitors of the dorsal brainstem and can be initiated in mice by transgenic expression of an activated mutant β-catenin (Ctnnb1) allele compounded with Trp53 deletion 52 . Sonic hedgehog (SHH) medulloblastomas have long been known to arise in cerebellar granule neuron precursors (CGNPs) of the cerebellar external granule cell layer (EGL) 64, 66, 169, 170 and, more recently, CGNPs derived from cochlear nuclei of the brainstem 67 . Neural stem cells (NSCs) residing in the subventricular zone (SVZ) are also capable of giving rise to SHH-dependent medulloblastoma 65 . Nearly all mouse models of SHH medulloblastoma rely on perturbations of the canonical SHH pathway in these respective cell types, with inactivation of Ptch1 and activation of smoothened (Smoa1) being the most commonly used initiating events. When combined with Trp53 inactivation, MYC-driven Group 3 medulloblastomas can be generated in at least three possible cell types: atonal homologue 1 (ATOH1)-positive CGNPs from the EGL 76 ; ATOH1-negative CGNPs from the EGL 76 ; and prominin 1-positive, lineage-negative NSCs 75 . The specific cellular origin or origins of Group 4 medulloblastoma have thus far remained elusive. However, targeted expression of MYCN, a bona fide SHH and Group 4 driver gene, to different NSC populations from the developing mouse brain generates either SHH-dependent or SHH-independent medulloblastomas, suggesting that the SHH-independent medulloblastomas may represent a faithful model of Group 4 medulloblastoma 79, 80 . 
Desmoplastic (or nodular) histology

Cerebellar granule neuron precursors
(CGNPs). As precursors to the most abundant neuron in the brain, CGNPs arise in the hindbrain during late embryonic development and migrate postnatally to the external granule cell layer of the cerebellum. They then undergo a period of massive proliferation before eventually migrating inwards to the internal granule layer and terminally differentiating.
Cochlear nuclei
Structures in the brainstem that derive from the auditory lower rhombic lip, receiving inputs on sound from the cochlear nerve. Cerebellar granule neuron precursors residing in the cochlear nuclei have been implicated as a possible cell-of-origin for sonic hedgehog medulloblastoma.
Isochromosome
An abnormal chromosome produced during mitosis or meiosis that is characterized by the presence of two genetically and morphologically identical chromosome arms fused at the centromere. Strictly, the common alteration of chromosome 17 in medulloblastoma is more often an isodicentric (17q), as the breakpoint is typically in the p-arm proximal to the centromere rather than at the centromere itself. chromosomes 1q, 7 and 17q, and deletions of 10q, 11, 16q and 17p 19 (TABLE 1) . Aberrations on chromosome 17 are usually attributed to the presence of an isochromosome 17 -i(17q).
In 2012, two independent groups published MYCdriven mouse models of Group 3 medulloblastoma that exhibit aggressive phenotypes similar to the human counterpart 75, 76 . Both of these models necessitate the loss of p53 activity to overcome MYC-induced apoptosis (TABLE 2) . Because TP53 is not directly mutated in human Group 3 medulloblastoma 49 , however, the search for more suitable candidates that cooperate with MYC in these tumours is currently underway. Nonetheless, the current models provide a good reagent for dissecting the biological basis of this poor outcome subgroup and for testing pharmacological agents that might help to selectively eradicate these tumours.
Group 4 medulloblastoma.
The most common subgroup of medulloblastoma is Group 4, accounting for about two in every five cases 19 (TABLE 1) . Childhood Group 4 patients have an intermediate prognosis similar to the SHH subgroup, but adults with Group 4 medulloblastoma may do significantly worse 19, 77 . There is a considerable gender bias in Group 4, with male cases being up to threefold more common than female cases. These tumours are mainly of classic histology but can be of the LCA phenotype, and metastases are found in about one-third of patients.
The proto-oncogenes MYCN and cyclin-dependent kinase 6 (CDK6) are recurrently amplified in Group 4 medulloblastomas, whereas they occur very rarely in Group 3 medulloblastoma 39, 40 . i(17q) is found in the majority of these cases, and most female Group 4 medullo blastomas lose one copy of the X chromosome, suggesting the existence of one or more TSGs. 
Indels
Mutations involving the insertion or deletion of nucleotides, which often lead to a loss of function by causing a shift in the reading frame of a gene.
There are currently no confirmed preclinical mouse models of Group 4 medulloblastoma 78 . An elegant transgenic mouse model that overexpresses both Mycn and luciferase using a bidirectional brain-specific promoter develops highly penetrant medulloblastomas that exhibit the properties of either SHH or non-SHH tumours, which may depend on the timing of tumour initiation 79, 80 (TABLE 2) . It is not yet clear whether the non-SHH tumours arising in these mice are accurate representations of MYCN-driven Group 4 medulloblastoma, but they do nonetheless provide a valuable tool for studying the role of MYCN in the context of medulloblastoma pathogenesis.
Mutational analysis of medulloblastoma
Until recently, only a handful of genes were recognized as recurrently mutated either in the germline or somatically in patients with medulloblastoma. These included the TSGs PTCH1, SUFU and TP53, and the oncogenes CTNNB1 and SMO 81 . Exceedingly rare mutations of APC, postmeiotic segregation increased 2 (PMS2), CREB-binding protein (CREBBP) and nibrin (NBS1) in individuals with hereditary syndromes who developed medulloblastoma have also been reported 20, 24, [82] [83] [84] . An important breakthrough in our understanding of the genetic landscape of medulloblastoma came in 2010, when Parsons et al. 85 published the first unbiased wholeexome sequencing study of medulloblastoma based on Sanger sequencing technology. Somatic mutations in histone methyltransferases (HMTs), mixed lineage leukaemia 2 (MLL2) and MLL3 were identified in 16% of cases, making them the first new candidate genes to be verified as recurrently mutated in medulloblastoma in nearly a decade. The bulk of the variants detected in these two histone modifiers were predicted to be inactivating, implying that they probably function as TSGs. Medulloblastoma subgroup status was unavailable for the samples included in this study and thus the subgroup distribution of MLL2 and MLL3 mutations was not reported. Mutations affecting the additional chromatin-associated genes SMARCA4, AT-rich interactive domain 1A (ARID1A) and lysine-specific demethylase 6B (KDM6B) were also revealed in this study, reinforcing the theme of deregulation of chromatin modifiers (discussed below) as a common mode to medulloblastoma pathogenesis, which was also implicated in prior copy number studies 73 .
Next-generation sequencing of medulloblastoma. In 2012, three independent next-generation sequencing studies of medulloblastoma were published [32] [33] [34] , which collectively screened whole genomes, whole exomes and prioritized lists of candidate genes across a cohort of 310 primary medulloblastoma specimens. These data represent the next important step in our understanding of medulloblastoma, in large part because each study identified a common set of novel recurrent mutations, providing a firm footing for further research.
The median number of somatic, non-silent mutations -single nucleotide variants (SNVs) and indelsper medulloblastoma genome seems to range from ten to 12, which is significantly lower than mutation rates reported in solid tumours that are typical of adulthood, including adult brain tumours [86] [87] [88] [89] [90] [91] . Likewise, a positive correlation between patient age and genomewide mutation rate was also observed 33, 34 . Indeed, preliminary analysis of the mutational spectra of adult medullo blastoma suggests that adults harbour significantly more somatic SNVs and indels than subgroupmatched paediatric counterparts (M.K., D.T.W.J., P.A.N. and S.M.P., unpublished observations). These observations might suggest that medulloblastoma, particularly when occurring in very young patients, requires the deregulation of only a minimal number of driver genes. An alternative explanation could be that SCNAs or epigenetic deregulation have a more prominent role in the initiation of paediatric medulloblastoma than point mutations. Indeed, SCNAs are common in non-WNT subgroups of medulloblastoma (as discussed below).
From the combined discovery cohorts of the three sequencing studies (n = 189), each medulloblastoma subgroup was represented at a frequency that was comparable to that reported in the literature 19 (FIG. 1a) .
Within the individual studies, some subgroup bias was evident, with Group 3 samples accounting for 36% of the Broad Institute cases 34 and Group 4 contributing 54% of the St. Jude cohort 32 -both of which are higher than expected frequencies for a typical medullo blastoma subgroup distribution 19 . As only a selection of candidate genes were sequenced in the verification cohorts from the German Cancer Research Center (DKFZ) 33 (n = 2,734 genes in 65 samples) and St. Jude 32 (n = 136 genes in 56 samples) studies, the denominators used in the calculation of mutation frequency varied according to gene. Among the combined discovery cohorts that aimed to interrogate every coding exon in the genome, a total of 2,102 unique genes were identified as somatically mutated. Of these, only 15 were reported as mutated in all three studies (FIG. 1b) . This limited list of commonly mutated genes includes titin (TTN), mucin 16 (MUC16) and ryanodine receptor 3 (RYR3), all of which are enormous genes (containing >300 exons in the case of TTN) that are routinely reported to be mutated in other sequencing studies 89 . The functional importance of these mutations is uncertain, as they might be mutated by chance alone (that is, they are passenger mutations) owing to their very large size; the mutations that have so far been documented have not substantially contributed to tumorigenesis. Indeed, when applying the MutSig algorithm (see Further information), which tests whether the observed mutations in a gene are simply a consequence of random background mutation processes by taking into account factors such as gene length, composition and silent to non-silent mutation ratios, none of these common passenger genes was found to be significantly mutated in the medulloblastoma-sequencing studies 33, 34 . Subtraction of these genes leaves just 12 high-confidence candidates on the basis of their detection in all three studies -suggesting that the list of prominent driver genes that are affected by somatic SNVs and indels in medulloblastoma is limited. 
The most common somatically mutated gene in medulloblastoma remains CTNNB1, sustaining activating SNVs in the third exon in 30 of 32 (91%) cases of WNT medulloblastoma across the combined cohort from all three papers (FIG. 1c,d ). One CTNNB1 mutation was found in a Group 3 tumour 32 , but this was the only exception and its importance is unknown.
Second to CTNNB1, the DEAD-box RNA helicase DDX3X is the next most frequently mutated gene in medulloblastoma (25 of 310; 8% (FIG. 1c) ). One-half of all WNT medulloblastomas (16 of 32) harboured mutations in DDX3X as did 11% (seven of 66) of SHH medulloblastoma cases (FIG. 1d) . DDX3X is dynamically linked to multiple cellular processes, including chromosome . b | Venn diagram showing the number of mutated genes identified in three next-generation sequencing studies of medulloblastoma (discovery cohorts, n = 189) and the degree of overlap between them. Fifteen genes were commonly mutated in all three studies. c | Frequency (percentage) and distribution of top candidate genes that are subject to recurrent non-synomonous mutation (single nucleotide variants (SNVs) and indels) in medulloblastoma subgroups. Frequency is expressed as the percentage of affected cases in each subgroup and the denominator was dependent on the total number of cases that were screened for each individual gene (as not all genes were included in the targeted replication cohorts). Genes highlighted in bold were found to be mutated in each of the three sequencing studies. d | Oncoprints showing the frequency and sample distribution of the most prevalent somatic mutations (SNVs and indels) and focal somatic copy number aberrations (SCNAs) in the medulloblastoma subgroups as determined in four genomic studies [32] [33] [34] 99 . BCOR, BCL6 co-repressor; CDH1, E-cadherin; CDK6, cyclin-dependent kinase 6; CHD7, chromodomain helicase DNA binding protein 7; CREBBP, CREB binding protein; CSNK2B, casein kinase 2β; CTDNEP1, CTD nuclear envelope phosphatase 1; CTNNB1, β-catenin; GABRG1, GABA A receptor-γ1; GLI2, GLI family zinc finger 2; KDM6A, lysine-specific demethylase 6A; LDB1, LIM domain binding 1; LRP1B, low density lipoprotein receptor-related protein 1B; MLL, mixed lineage leukaemia; NA, not available; OTX2, orthodenticle homeobox 2; PIK3CA, PI3K catalytic-α polypeptide; PTCH1, patched 1; SHH, sonic hedgehog; SNCAIP, α-synuclein interacting protein; SPTB, spectrin-β erythrocytic; TCF4, transcription factor 4; TNXB, tenascin XB.
segregation, cell cycle regulation, transcription and translation [92] [93] [94] [95] [96] [97] . Through mapping of the mutations to its crystal structure [32] [33] [34] 98 , it seems that the mutations alter DDX3X-RNA binding and are likely to result in altered protein function as opposed to loss of function. Moreover, nearly all SNVs reported in DDX3X affect either of its two helicase domains, which suggests that these mutations affect the functionality of these domains (FIG. 2) . Functional studies investigating the impact of DDX3X mutations either in vitro or in vivo strongly suggest that DDX3X SNVs enhance cellular proliferation by potentiating the transactivation capacity of mutant β-catenin 32, 34 and that DDX3X is required to maintain the lineage of LRL progenitors (LRPs) 32 , the proposed WNT medulloblastoma cells-of-origin 52 .
As expected, PTCH1 mutations were restricted to SHH (16 of 66; 24% (FIG. 1c,d) ). Similarly, TP53 mutations, all of which mapped to the DNA-binding domain of p53, were distributed as previously reported 49 and were absent in all of the 76 cases of Group 3 medullo blastoma that were profiled. Mutations affecting MLL2 were found in all subgroups (18 of 310; 6% overall) but were enriched in both WNT and SHH medullo blastomas compared with Group 3 and Group 4 medullo blastomas. Conversely, MLL3 mutations were less common than mutations of MLL2 (n = 8 of 310 versus 18 of 310, respectively) and were found only in Group 3 and Group 4 medullo blastoma. SMARCA4, which had previously been implicated in medulloblastoma 85 , was frequently targeted in both WNT (8 of 32; 25%) and Group 3 (8 of 76; 11%) medulloblastomas, making it among the top five most commonly mutated genes in medulloblastoma (FIG. 1c,d ).
Histone modifiers in medulloblastoma. The deregulation of factors involved in the covalent post-translational modification of histones, in particular HMTs, histone demethylases (HDMs), histone acetyltransferases (HATs) and histone deacetylases (HDACs), as well as various other chromatin-associated genes, has been repeatedly identified as occuring in medullo blastoma [32] [33] [34] 73, 85 . Indeed, of the recurrently mutated genes that were identified in the next-generation sequencing studies (n = 335), 24 are predicted to function in processes that are related to chromatin, based on Gene Ontology (GO) analysis (the GO term is chromatin modification), affecting 33% (62 of 189) of medulloblastomas (FIG. 3; TABLE 3 ). Additional chromatinassociated genes seem to be preferentially altered by SCNAs 73, 99 , although not to the same extent as those sustaining SNVs and indels.
In addition to the previously described mutations affecting MLL2, MLL3 and SMARCA4, several new candidates that share similar functionality have emerged. KDM6A (also known as UTX), a histone H3 Lys27 (H3K27) demethylase 100, 101 , is the most frequently mutated gene in Group 4 medulloblastoma (13 of 108; 12% (FIG. 1c,d) ). KDM6A belongs to the Jumonji C family of HDMs that also includes KDM6B 102 , which was also reported to be mutated in medulloblastoma 85 . Ten of 16 mutations that affect KDM6A were nonsense mutations, implicating it as a novel medulloblastoma TSG (FIG. 2) . Likewise, the KDM6A locus on chromosome Xp11.3 was reported as homozygously deleted in multiple cases of Group 4 medulloblastoma that were profiled in the recent Medulloblastoma Advanced Genomics International Consortium (MAGIC) copy number study (discussed below) 99 , further substantiating its potential importance in Group 4 biology.
Additional chromatin remodelling genes, ZMYM3 and chromodomain helicase DNA binding protein 7 (CHD7) [103] [104] [105] [106] , are also recurrently mutated in Group 4 medulloblastoma (FIG. 1c) . Robinson et al. 32 proposed a connection between KDM6A, ZMYM3 and CHD7 mutations and enhancer of zeste homologue 2 (EZH2) activity. EZH2 is an H3K27 methyltransferase that functions to maintain the undifferentiated state of stem cells by repressing the expression of lineage-specific genes 107, 108 , essentially opposing the H3K27 demethylase activity of KDM6A, which promotes differentiation. EZH2 is selectively overexpressed in Group 3 and Group 4 medulloblastoma, particularly in cases that exhibit chromosome 7 gain 32, 109 , and EZH2 inhibition has been shown to suppress medulloblastoma cell growth and to promote apoptosis 109 .
Robinson et al. 32 demonstrated a mutually exclusive correlation between the copy number-driven expression of EZH2 and the inactivating mutations affecting KDM6A, CHD7 and/or ZMYM3 as alternative, but complementary, mechanisms of maintaining constitutive trimethylation (me3) of H3K27 in Group 3 and Group 4 medulloblastoma. Although these observations provide an attractive model for the disruption of physiological H3K27me3 in these subgroups, functional experiments will be required to validate this relationship. Several genes associated with chromatin modification also seem to be specifically mutated at fairly modest frequencies in the SHH medulloblastoma subgroup (FIG. 1c,d ). Mutations that target components of the nuclear receptor co-repressor (N-CoR) complex 110 , BCL6 co-repressor (BCOR) and LIM domain-binding 1 (LDB1), were mutually exclusive in SHH medulloblastoma and collectively accounted for 14% (8 of 58) of cases (FIG. 1d) . All BCOR mutations were truncating, as were two of four mutations affecting LDB1, suggesting that these genes undergo loss-of-function in SHH medulloblastoma (FIG. 2) . The N-CoR complex is associated with HDAC activity and is thought to mediate transcriptional repression by influencing the deacetylation and condensation of chromatin 110 . Recurrent mutations affecting this complex in SHH medulloblastoma, taken together with the apparent deregulation of H3K27 methylation described in Group 3 and Group 4, strengthens the argument that disruption of the histone code seems to occur across subgroups of medulloblastoma and continues to evolve as one of the most prominent themes underlying medulloblastoma pathogenesis (FIG. 3) .
Correlation between SNVs and SCNAs. Efforts to integrate different sources of genomic data in order to extract biologically meaningful information remain a centrally important challenge in bioinformatics 111 , and few studies have accomplished such a feat on a global scale. But there are examples of genes that are targeted by multiple mechanisms (such as SNVs, indels and SCNAs). (FIG. 1c,d) . Additionally, BCOR, DDX3X and KDM6A occur in a region on chromosome X (Xp11.4-p11.3) that is the target of both recurrent focal deletions and broad (that is, whole-chromosome and chromosome arm) deletions in medulloblastoma 99 . A novel candidate gene, CTD nuclear envelope phosphatase 1 (CTDNEP1; also known as DULLARD), was identified as a recurrent target of mutation in Group 3 and Group 4 medulloblastomas (four cases from these subgroups; two cases without subgroup information available) and all but one were nonsense mutations (FIG. 2) . CTDNEP1 encodes a nuclear envelope serine/threonine phosphatase that is thought to function as an antagonist of bone morphogenetic protein (BMP) signalling that regulates neural induction in Xenopus laevis 112 . In mammals, it is involved in lipin pathway activation, which is responsible for the formation of diacylglycerol 113, 114 . CTDNEP1 occurs on chromosome 17p13.1, a hotspot of deletion and loss of heterozygosity (LOH) in medulloblastoma [115] [116] [117] , especially in Group 3 and Group 4. Indeed, most (five of six) CTDNEP1 mutations were homozygous as a result of a corresponding 17p deletion in the same tumours. Although CTDNEP1 is unlikely to be the sole TSG that is important on 17p in medulloblastoma, this observation convincingly qualifies CTDNEP1 as a candidate TSG, and as such warrants further functional characterization. [32] [33] [34] . Genes are depicted in the subgroup for which they show the greatest enrichment. In Group 3, the box adjacent to MYC depicts the general structure of the recurrent PVT1-MYC fusion genes reported by Northcott et al. 99 . In Group 4, the box adjacent to α-synuclein-interacting protein (SNCAIP) illustrates the general structure of the SNCAIP tandem duplications described by Northcott et al. 99 . ANK, ankyrin repeat; BCOR, BCL6 co-repressor; Chr, chromosome; CTDNEP1, CTD nuclear envelope phosphatase 1; HLH, helix-loop-helix domain; JmjC, Jumonji C domain; KDM6A, lysine-specific demethylase 6A; LDB1, LIM domain binding 1; NIF, NLI interacting factor-like phosphatase domain; nt, nucleotide; SHH, sonic hedgehog; TPR, tetratricopeptide repeat. 
Tetraploidy
A whole-genome duplication event such that each chromosome is present as four, rather than two, copies.
Inspection of the key driver mutations identified in the sequencing studies and their respective sample distribution in the individual subgroups has led to some intriguing observations (FIG. 1d) . Specifically, 100% of WNT medulloblastomas in the combined discovery cohorts (n = 18 of 18) have mutations in only a handful of genes. This suggests that WNT medulloblastoma is the most homogenous of the four subgroups and may represent the best candidate for future targeted therapies, because most patients will share similar mutational profiles. Likewise, most (28 of 42; 67%) SHH medulloblastomas are associated with recurrent somatic mutations -without considering the potential contribution of common germline mutations in known TSGs: PTCH1, SUFU and TP53. By contrast, only 31% (16 of 52) of Group 3 and 20% (14 of 69) of Group 4 medulloblastomas are associated with the more common SNVs and indels reported in these subgroups (FIG. 4) . Overlay of gains and losses of significantly altered chromosomes in Group 3 and Group 4 medulloblastoma reveals that cases that are devoid of SNVs and indels exhibit more pronounced chromosomal instability (CIN) -that is, broad SCNAs -than those harbouring mutations (FIG. 4) . Collectively, these observations suggest that up to two-thirds of all Group 3 and Group 4 medulloblastomas are more likely to be driven by SCNAs (or alternative mechanisms) than by SNVs and indels. Although this requires validation, the large proportion of Groups 3 and 4 medulloblastomas that seemingly lack any obvious individual driver mutation or mutations is an unexpected finding, warranting further investigation to determine what is driving tumorigenesis in this large subset of patients. Likewise, it will be important to establish whether the respective genotypes of these SNV-impoverished medulloblastomas confer a better or worse patient outcome.
Structural variation in medulloblastoma
Although considerable attention has been devoted to the newly identified, recurrent somatic SNVs and indels in medulloblastoma, an equally compelling case can be made for the novel findings that are attributable to structural variation. In Group 3 and Group 4 medulloblastoma, focal SCNAs seem to account for as many cases, as do SNVs, which underscores the importance of considering all possible mechanisms of mutation when tallying potential driver events. Additional forms of structural variation that affect the integrity of the genome, including chromothripsis and tetraploidy, have both been described as occuring in specific medulloblastoma subgroups 33, 35, 99 , and they provide new explanations for some of the distinct genomic architecture that has been previously underappreciated in this genome.
SCNAs.
Array-based genome-wide copy number analyses of medulloblastoma have been ongoing for the better part of a decade 81 . Most studies have identified prevalent cytogenetic anomalies in medulloblastoma, including i(17q) Figure 3 | Convergent deregulation of the histone code in medulloblastoma. A diagram summarizing a selection of genes that are recurrently mutated and/or undergo somatic copy number aberrations (SCNAs) in medulloblastoma that are functionally associated with chromatin regulation. Both inactive heterochromatin and active euchromatin and the typical histone marks associated with these chromatin states are illustrated. Ac, acetylation; ARID1B, AT-rich interactive domain 1B; BCOR, BCL6 co-repressor; CHD7, chromodomain helicase DNA binding protein 7; CTCF, CCCTC-binding factor; CREBBP, CREB binding protein; EHMT1, euchromatic histone-lysine N-methyltransferase 1; EP300, E1A binding protein p300; EYA4, eyes absent homologue 4; HDAC, histone deacetylase; KAT6A, lysine acetyltransferase 6A; KDM, lysine-specific demethylase; LDB1, LIM domain binding 1; Me, methylation; MLL, mixed lineage leukaemia; P, phosphorylation; Pol, polymerase; REST, RE1-silencing transcription factor; SETD2, SET domain containing 2; TLK2, tousled-like kinase 2; TRRAP, transformation/transcription domain-associated protein.
and isolated chromosome 17 alterations, monosomy 6, deletion of chromosomes 9q, 10q and 16q, and gain of chromosomes 1q, 7 and 18 -many of which are now recognized as enriched in a particular subgroup or subgroups 19 . Focal, oncogenic amplifications of MYCN, MYC, GLI2, CDK6 and orthodenticle homeobox 2 (OTX2) have been the most widely noted 39, 40, 73, [118] [119] [120] [121] . Aside from these characteristic aberrations, most copy number studies of medulloblastoma have investigated an insufficient number of samples to adequately account for the inherent heterogeneity of medulloblastoma, especially according to molecular subgroup.
However, a large international study led by MAGIC has now described SCNAs in a collection of 1,087 primary medulloblastoma samples 99 . WNT medulloblastomas (n = 76) were confirmed to exhibit almost no significant regions of focal SCNA. By contrast, SHH medulloblastomas are characterized by frequent focal, high amplitude SCNAs (that is, high-level amplifications and homozygous deletions). In addition to SCNAs targeting prominent SHH pathway genes, many new genes were found to be recurrently affected by SCNA in SHH medulloblastomas, especially those involved in either p53 or receptor tyrosine kinase (RTK)-PI3K signalling 99 . High-level amplification of protein phosphatase 1D (PPM1D) on chromosome 17q23.2, a gene that has previously been reported to be amplified in medulloblastoma 120 , was found to exclusively occur in SHH medulloblastomas. PPM1D encodes WIP1, a p53-induced phosphatase that inhibits wild-type p53 activity 122 . WIP1 is aberrantly expressed in medulloblastomas 123 and promotes the development of SHH medulloblastoma in mice 124 . Paradoxically, broad gains of chromosome 17q are extremely rare in cases of SHH medulloblastoma but are common in Group 3 and Group 4, suggesting that PPM1D amplification is specific to SHH and distinct from the target or targets of 17q gain in other subgroups.
Genes associated with RTK-PI3K signalling were also selectively altered in SHH medulloblastoma, including amplifications of insulin-like growth factor 1 receptor (IGF1R), insulin receptor substrate 2 (IRS2), 
Tandem duplication
A structural variant caused by a duplication event that results in two genomic segments of at least 1kb in size that share >90% sequence identity positioned in a contiguous manner within the genome.
PIK3C2G, PIK3C2B and yes-associated protein 1 (YAP1), as well as focal deletions of PTEN on chromosome 10q23.31. PTEN was the most frequent target of homozygous deletion in the MAGIC cohort, occurred exclusively in paediatric SHH cases, and is a prominent candidate target for the characteristic chromosome 10q deletions that are observed in SHH. The apparently specific deregulation of PI3K signalling in SHH medulloblastoma is poignant because combination therapy consisting of inhibitors of both SHH (that is, SMO) and PI3K pathways has shown preliminary efficacy in preclinical SHH medulloblastoma mouse models, delaying, preventing or overcoming the resistance that is encountered in response to treatment with SMO inhibitors alone 70, 71 . Despite some clear underlying similarities, Group 3 and Group 4 medulloblastomas exhibit distinct patterns of broad and focal SCNAs that permit their discrimination 19 . Group 3 medulloblastomas more commonly sustain chromosome 1q gains and deletions on 5q, whereas chromosome 4 gains and deletion of X (in females) are more frequently seen in Group 4 medulloblastomas [38] [39] [40] . With respect to driver genes altered by SCNAs, MYC amplifications predominate in Group 3 (30 of 178; 17% of Group 3 cases in the MAGIC study) 99 (FIG. 1d) . Fusion transcripts involving MYC and PVT1 (that is, PVT1-MYC) have also been identified in at least 60% of MYC-amplified Group 3 medulloblastomas 99 (FIG. 2) . PVT1 is a non-coding gene mapping adjacent to MYC on chromosome 8q24.21 that also encodes multiple microRNAs (miR-1204-1207); some reports suggest that these miRNAs enhance the oncogenic properties of MYC [125] [126] [127] . PVT1-MYC fusions are the first recurrent gene fusions reported in medulloblastoma, adding further complexity to the role of MYC in driving Group 3 medulloblastoma tumorigenesis.
Tandem duplication. A novel, and somewhat subtle, structural aberration that became apparent in the Group 4 medulloblastoma samples (n = 317) in the MAGIC cohort concerns focal, single copy gain of α-synucleininteracting protein (SNCAIP) on chromosome 5q23.2 (REF. 99 ). SNCAIP encodes synphilin 1, a binding partner of α-synuclein that constitutes the major component of the characteristic protein aggregates (known as Lewy bodies) that occur in Parkinson's disease [128] [129] [130] . SNCAIP gains were confined to Group 4 medulloblastoma and were found in ~25% of Group 4α, a subtype of Group 4 medulloblastoma that is characterized by a mostly balanced genome 39, 99 . SNCAIP gains are the result of a highly stereotypical tandem duplication juxtaposing a slightly truncated SNCAIP gene adjacent to the germline allele (FIG. 2) . Results from multiple published expression data sets suggest that SNCAIP is a bona fide Group 4 signature gene that may represent a lineage marker for the yet to be identified Group 4 cell-of-origin 99 . Recurrent tandem duplication of SNCAIP in Group 4 places this candidate among the relatively few genes that are altered by this mechanism in cancer, including the highly prevalent BRAF duplications that are observed in another paediatric brain tumour, pilocytic astrocytoma 131, 132 .
Chromothripsis. Individuals with Li-Fraumeni syndrome (LFS) harbour germline TP53 mutations 133, 134 and are predisposed to the development of a variety of different cancers, including SHH medulloblastoma 12 . To investigate the somatic mutations that cooperate with germline inactivation of TP53 in medulloblastoma, Rausch et al. 35 carried out whole-genome sequencing (WGS) on a female patient with LFS who had developed SHH medulloblastoma. Strikingly, the genome of this case was characterized by a very complex series of somatic rearrangements, which included fusions of multiple highly amplified regions clustered on individual chromosomes (intrachromosomal), as well as those from different chromosomes (interchromosomal) that were organized as double-minute chromosomes. The pattern of rearrangements observed in this index case was inferred as prototypical chromothripsis, as originally defined by Stephens et al. 135 . Further genomic analyses verified an intricate relationship between TP53 mutation and chromothripsis in SHH medulloblastomas 35 . Moreover, multiple oncogenes that are relevant to the SHH subgroup, including MYCN, GLI2, BOC and IGF1R, were shown in this study to be selectively amplified in the context of chromothripsis, providing a mechanism for their deregulation in SHH. Demographically, LFS-SHH medulloblastomas show a clear enrichment in childhood and early adolescence (~8-14 years of age), constituting a subtype of SHH medulloblastoma that is both genetically and clinically distinct from the more common infant and adult subtypes 33 . Amplification patterns associated with chromothripsis were also reported in the MAGIC study 99 . Interestingly, a considerable number of MYC-amplified, PVT1-MYC fusion-positive cases of Group 3 medulloblastoma were inferred by single nucleotide polymorphism (SNP) array and verified by WGS as probable chromothripsis candidates. As TP53 mutations are almost absent in Group 3 medulloblastomas, alternative, p53-independent mechanisms could be responsible for the chromothripsis that is observed in this subgroup.
As chromothripsis seems to be tightly linked to specific patient subsets, it may prove beneficial to identify these patients early in the course of treatment so that they can be stratified accordingly and their therapeutic regimens adjusted. Indeed, in patients with LFS and SHH medulloblastoma, it may be advantageous to avoid the administration of excessive DNA-damaging agents (such as alkylating drugs) and radiotherapy, given that their underlying genotypes confer a high risk of secondary malignancies.
Tetraploidy. Aneuploidy has been recognized as a hallmark feature of cancer cells for more than a century 136 . Similarly, polyploidy, ranging from hypodiploid cells consisting of considerably fewer than 46 chromosomes, to hypertetraploid cells that can harbour up to 200 chromosomes, has long been observed in tumour cell karyotypes 137, 138 . Early karyotyping studies of primary medulloblastoma samples and patient-derived medulloblastoma cell lines found that aneuploidy and polyploidy, including tetraploidy, commonly occurred [139] [140] [141] [142] [143] [144] . Jones et al. 33 identified an unexpectedly high number of tetraploid medulloblastomas through the inspection of mutant allele frequencies, with a sizable proportion observed at 25% as opposed to the expected 50% allele frequency for clonal heterozygous mutations. Tetraploidy mostly occurred in Group 3 and Group 4 medulloblastomas (~40-50%). Of particular interest, all of the tetraploid SHH medulloblastomas exhibited TP53 mutations and chromothripsis. Although the biological and clinical importance of tetraploidy in medulloblastoma requires further investigation, several recent studies have suggested that tetraploidization is associated with CIN and can drive tumorigenesis in mice 145, 146 . Tetraploid cells are also known to be more resistant to chemotherapy and radiotherapy than diploid cells, which might partially account for the poor response of these patient subgroups, particularly Group 3, to standard therapies 147 . Thus, targeting the maintenance of a tetraploid state through successive cell divisions using novel classes of drugs, such as inhibitors of mitotic checkpoint kinases or kinesins, may serve as an attractive therapeutic option for a considerable subset of medulloblastomas 148, 149 .
Medulloblastoma in the 'post-genomics' era Medulloblastoma predisposition. Most, if not all, nextgeneration genomic approaches to studying medulloblastoma have so far exclusively focused on alterations present in the tumour that were somatically acquired during tumorigenesis. As a result, the germline of individuals who go on to develop medulloblastoma is mostly unexplored, leaving a lot of open questions regarding the potential contribution of germline variants to medulloblastoma predisposition and development. Is there more to the medulloblastoma germline than mutations in only the well-known hereditary cancer genes, PTCH1, SUFU and TP53? Historical estimates are that <5% of medulloblastomas can be attributed to underlying predisposition 150, 151 . Could this be a gross underestimate of the true frequency of causative germline mutations in these patients? Concerted efforts focused on answering these questions will necessitate the next-generation sequencing of large numbers of germline samples obtained from patients with medulloblastoma and healthy controls, followed by cataloguing of pathogenic variants that are present in affected individuals. Although such a study will undoubtedly pose considerable challenges, particularly when attempting to identify pathogenic variation, it is anticipated that such a comprehensive investigation will yield novel candidates that predispose to medulloblastoma and could potentially provide an explanation for some of the cases that currently cannot be accounted for by known somatic alterations.
Double-minute chromosomes
Typically acentric, extrachromosomally amplified chromatin, usually containing a particular chromosomal segment or gene. Double minutes are common in cancer and often result in oncogene amplification through replication and asymmetric distribution after cell division.
Single nucleotide polymorphism
(SNP). A single nucleotide DNA sequence variant that differs between individuals or paired chromosomes from the same individual. In contrast to single nucleotide variants, these are present in the normal genome of an individual.
Aneuploidy
An abnormal number of chromosomes.
Beyond the coding genome. Given that many of the ongoing sequencing projects are based on WGS, the ability to look outside the roughly 2% of the genome that codes for proteins and functional RNAs is now feasible. Few investigations have so far been focused on the potential consequences of somatic intergenic mutations or SCNAs. Although a daunting task when considering the large number of SNPs that exist in an individual 152, 153 , recurrent mutations that affect promoters, enhancers and other regulatory elements may have profound effects on neighbouring genes and will undoubtedly be a worthwhile area of further investigation. In medullo blastoma, it will be interesting to identify non-coding DNA mutations that are enriched or restricted to a particular subgroup and to subsequently link these alterations with driver genes in that subgroup.
Integrative genomics. Now that detailed maps of the most prominent SCNAs, SNVs and indels that contribute to medulloblastoma have been outlined, epigenetic alterations, including the DNA methylome and genomewide maps of histone modifications, will become a priority 154, 155 . Moreover, the capacity to identify recurrent gene fusions, alternative splicing events and previously unreported gene products is now possible with RNA sequencing (RNA-Seq) technology 156 , and large-scale RNA-Seq projects of medulloblastoma are currently underway.
The integration of medulloblastoma genomic, epigenomic and transcriptional data is likely to result in a much greater depth of knowledge. A seminal breast cancer study consisting of nearly 2,000 biopsy samples recently combined SCNA and gene expression data generated from these samples, ultimately revealing novel subgroups of the disease with distinct clinical outcomes 157 . Likewise, a recent study of colorectal cancer systematically analysed exome sequence, SCNAs, promoter methylation and the transcriptome (mRNA and miRNA) in 276 cases, unveiling distinct genomic patterns in hypermutated versus non-hypermutated disease 90 . Such integrative approaches have not yet been applied to medulloblastoma but are undoubtedly on the horizon. The simple comparison of cytogenetic events with somatic SNVs and indels (as discussed here) suggests that future, integrative efforts will yield further insights into medulloblastoma, especially into the clinically challenging Group 3 and Group 4 medulloblatomas, the pathogenesis of which cannot be entirely explained by the SCNA and mutational data that are currently available.
Remaining challenges in medulloblastoma genomics.
The next challenge faced by the medulloblastoma research community will be to discriminate true driver events from passengers that provide no selective advantage to the tumours 158, 159 . The functional importance of high-priority candidates such as DDX3X has already been assessed, but the individual verification of all genes that undergo recurrent focal SCNA or mutation in medulloblastoma is unrealistic. Methodical candidate evaluation will require broader and more sophisticated approaches, such as the use of in vivo RNA interference 160, 161 and modern mutagenesis screens such as the sleeping beauty (SB) transposon system 162 , which has already demonstrated utility in medulloblastoma studies 163 . Studies comparing the genomics of primary tumours with their matched metastases or relapses should also be undertaken. Wu et al. 163 identified dramatic differences in the genes targeted in primary medulloblastomas compared with matched metastases in mice; a trend that was supported in paired primary and metastatic human medulloblastoma biopsy samples. Genomic studies further assessing the similarity of primary medulloblastomas with their matched metastases or relapses will be crucial to elucidate whether the mutations required for the primary tumour are maintained in resistant disease and likewise to discover the alterations that are prevalent in metastases and relapses but that are absent or subclonal in the primary tumour. This information is particularly important because metastases and relapsed disease account for most of the morbidity that is associated with medulloblastoma [164] [165] [166] . Most, if not all, neuro-oncologists and neuropsychologists would attest that the current treatment options for medulloblastoma remain inadequate 6, 167 . The search for new therapeutic options in the form of small molecules targeting the pathways and processes that are recurrently altered in medulloblastoma subgroups, or the specific cell types that are responsible for tumour maintenance, will clearly become the focus of many laboratories. High-throughput drug screens for agents with activity against medulloblastoma are now in progress. In order to effectively test large libraries of compounds for the treatment of medulloblastoma, not only will representative preclinical models of each medullo blastoma subgroup be required, but also multiple different models of each subgroup mimicking the prevalent mutations and SCNAs observed in the human disease will be necessary. Once established, these transgenic mice, xenografts, primary cells and immortalized cell lines will be challenged with thousands of small molecules, ideally those that have already been approved by the US Food and Drug Administration (FDA), in order to pinpoint new therapies that are less toxic and more effective for specific patient subgroups or even individual patients. Finally, early testing of targeted therapy for medullo blastoma suggests that combination therapy will be required to cure the disease and to prevent acquired resistance 10 . This implies that not only will thousands of compounds need to be tested, but also seemingly infinite combinations of small molecules might be necessary to uncover the best 'recipe' for individualized disease eradication. Focused screens intended to target specific genes and gene families, such as agents that inhibit the activity of chromatin modifiers, or specific karyotypes such as those selective for tetraploid cells, are also equally likely given the findings from the recent genomic studies.
Conclusions
An immense amount of genomic data has identified multiple candidate genes that contribute to the pathogenesis of different subgroups of medulloblastoma.
The RNA helicase DDX3X, chromatin regulators KDM6A and ZMYM3, N-CoR complex genes BCOR and LDB1, and the Parkinson's disease gene SNCAIP are among a host of novel, somatically targeted genes that show clear enrichment in a particular medulloblastoma subgroup. Other candidates, including MLL2 and SMARCA4, sustain mutations in multiple subgroups, suggesting that they might have a broader role in medulloblastoma biology. Indeed, the next phase of research will be aimed at functional validation, and will lead to an improved understanding of how specific mutations and SCNAs contribute to the initiation, maintenance and progression of the disease. Likewise, tetraploidy and chromothripsis provide new insights into the broader mechanisms of structural variation in medulloblastoma and raise the possibility of therapeutically targeting these processes, as opposed to targeting a single gene or pathway. Finally, the interplay between mutations and structural variation, as well as the importance of the medulloblastoma epigenome and the complexity of the transcriptome, will all be better understood through integrative genomic studies. As can be concluded from the studies presented here, the first phase of next-generation 'medulloblastomics' has reached a milestone, but this is probably just the end of the beginning.
